Core Viewpoint - The company is actively seeking partnerships both domestically and internationally to promote the globalization of traditional Chinese medicine [1] Group 1 - The company's products, including Yuanhu Zhitong Diban and Huangqi Danggui Capsules, have been registered and are being sold in Thailand [1]

Core Viewpoint - The company is actively seeking partnerships both domestically and internationally to promote the globalization of traditional Chinese medicine [1] Group 1: Company Developments - The company has successfully registered and is selling its products, Yuanhu Zhitong Droplets and Huangqi Danggui Capsules, in Thailand [1]

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - Sarepta's gene therapy Elevidys has shown positive results in its Phase 3 clinical trial, maintaining higher than baseline scores in the North Star Ambulatory Assessment (NSAA) after three years in patients treated at an average age of 9 [5]. - The pharmaceutical sector experienced a decline of 1.11% on January 27, 2025, underperforming the CSI 300 index by 1.08 percentage points, ranking 27th among 31 sub-industries [4]. - Among sub-industries, other biological products (+0.13%) and in vitro diagnostics (-0.07%) performed well, while vaccines (-3.55%) and offline pharmacies (-2.69%) lagged [4]. Sub-industry Summary - Chemical Pharmaceuticals: No rating [3] - Traditional Chinese Medicine: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other Pharmaceutical Industries: Neutral [3]

Core Viewpoint - Gansu Longshen Rongfa Pharmaceutical Co., Ltd. expects a net profit of 42 million to 48.5 million yuan for the fiscal year 2025, representing a growth of 79.59% to 107.38% compared to the same period in 2024, driven by cost control and supply chain management [1] Financial Performance - The company anticipates a net profit attributable to shareholders of 42 million to 48.5 million yuan for 2025, marking a significant increase from the previous year [1] - Non-recurring gains and losses are expected to impact net profit by approximately 4 million yuan [1] Product and Market Position - The core support for the company's performance comes from its unique products, Yuanhu Zhiting Droplets and Xuanfei Zhiso Mixture, which maintain strong market positions [2] - A new production line for Xuanfei Zhiso Mixture with an annual capacity of 50 million boxes has passed GMP compliance checks and commenced production in August 2025 [2] Research and Development - The company has upgraded its research facilities and established multiple R&D platforms, including a significant acquisition of 70% of Gansu Pharmaceutical Group Technology Innovation Research Institute [3] - The company is advancing its product development, including the registration application for a new drug, and has launched several health products to enhance its product portfolio [3] International and Diversification Efforts - The company achieved important milestones in internationalization, with its health product, Huangqi Danggui Capsules, receiving official certification in Macau, facilitating market expansion [4] - New medical products, including blood dialysis powder and concentrated solutions, have received regulatory approval, paving the way for future production and sales [4]

经济观察网2026年1月27日，陇神戎发（300534）发布2025年度业绩预告，预计2025年净利润4200万元 至4850万元，同比增长79.59%至107.38%；扣除非经常性损益后的净利润4600万元至5250万元，同比增 长0.84%至15.09%。 ...

新京报贝壳财经讯 1月27日，陇神戎发公告，预计2025年度净利润为4200万元–4850万元，同比增长 79.59%-107.38%。报告期内，公司持续强化成本管控与供应链协同管理，严控各项期间费用，持续推进 降本增效，公司盈利能力得到提升。 ...

业绩变动原因说明：1.报告期内，公司持续强化成本管控与供应链协同管理，严控各项期间费用，持续 推进降本增效，公司盈利能力得到提升。2.报告期内，公司预计非经常性损益对净利润的影响金额约为 400万元。 格隆汇1月27日丨陇神戎发(300534.SZ)公布，预计2025年1月1日至2025年12月31日归属于上市公司股东 的净利润盈利：4200万元-4850万元，比上年同期增长：79.59%-107.38%；扣除非经常性损益后的净利 润盈利：4600万元-5250万元，比上年同期增长：0.84%-15.09%。 ...

陇神戎发公告称，2025年1月1日至12月31日，预计归属于上市公司股东的净利润为4200万元-4850万 元，同比增长79.59%-107.38%；扣除非经常性损益后的净利润为4600万元-5250万元，同比增长 0.84%-15.09%。业绩变动因公司强化成本管控与供应链协同，严控费用、降本增效，且预计非经常性损 益影响约400万元。2025年3月，公司完成收购创新研究院70%股权，按同一控制下企业合并原则追溯调 整上年同期数。 ...

陇神戎发公告，预计2025年度净利润为4200万元–4850万元，同比增长79.59%-107.38%。报告期内，公 司持续强化成本管控与供应链协同管理，严控各项期间费用，持续推进降本增效，公司盈利能力得到提 升。 ...

证券代码：300534 证券简称：陇神戎发 公告编号：2026-001 | 项目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司 | 盈利：4,200 万元–4,850 万元 | 盈利：2,338.70 万元 | | 股东的净利润 | 比上年同期增长：79.59%–107.38% | | | 扣除非经常性损 | 盈利：4,600 万元–5,250 万元 | 盈利：4,561.68 万元 | | 益后的净利润 | 比上年同期增长：0.84%–15.09% | | 说明：2025 年 3 月 21 日，公司召开第五届董事会第十六次会议，审议通过 了《关于现金收购甘肃药业集团科技创新研究院有限公司 70%股权暨关联交易的 议案》，公司以自有资金收购甘肃药业投资集团有限公司持有的甘肃药业集团科 技创新研究院有限公司（以下简称"创新研究院"）70%股权。2025 年 3 月 29 日，创新研究院取得了兰州市市场监督管理局高新技术产业开发区分局下发的 《变更通知书》，标的资产完成过户登记。本期业绩预告中对上年同期数按照同 一控制下企业合并原则进行追溯调整列示。 二、与会计师事务 ...